A pilot study with monosialoganglioside GM1 on acute cerebral ischemia.
Reported here are the results of an open controlled study on the use of GM1 in cases of ischemic strokes in its acute phase. A statistically significant improvement was observed in cases treated with GM1 for neurological deficits (assessed by Mathew's rating scale, modified by Fritz-Werner) at 21, 60 and 120 days and for disability at 120 days.
Institute of Clinical Neurology, Pisa University.
C
C
Giraldi
M C
MC
Masi
M
M
Manetti
E
E
Carabelli
A
A
Martini
D000208:Acute Disease; D000368:Aged; D005732:Gangliosides / Q000627:therapeutic use*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy*; D008875:Middle Aged; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic
D005732:Gangliosides; C025447:sialogangliosides